The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association September 10, 2019 September 10, 2019
MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP September 4, 2019 September 4, 2019
MedinCell partners to address the untapped financial potential in Animal Health August 28, 2019 August 28, 2019
Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities August 26, 2019 August 26, 2019
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development July 9, 2019 July 9, 2019
Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019 May 22, 2019 May 22, 2019
MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management March 11, 2019 March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive January 24, 2019 January 24, 2019
